Filtros de búsqueda

Lista de obras de

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia

artículo científico publicado en 2015

14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia

artículo científico publicado en 2009

A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition

artículo científico publicado en 2013

A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib

artículo científico publicado en 2014

A case report of acute myeloid leukemia and neurofibromatosis 1.

artículo científico publicado en 2013

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

artículo científico publicado en 2012

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

artículo científico

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

artículo científico publicado en 2012

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

artículo científico publicado en 2013

A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia

artículo científico publicado en 2012

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

artículo científico publicado en 2013

A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia

artículo científico publicado en 2011

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

artículo científico publicado en 2016

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

artículo científico publicado en 2009

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

artículo científico publicado en 2002

A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG).

artículo científico publicado en 2015

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial

artículo científico publicado en 2008

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology

AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile.

artículo científico publicado en 2011

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms

artículo científico publicado en 2012

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

artículo científico publicado en 2006

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

artículo científico publicado en 2016

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

artículo científico publicado en 2013

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2012

Advanced mast cell disease: an Italian Hematological Multicenter experience

artículo científico publicado en 2008

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia

artículo científico publicado en 2006

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

artículo científico

Advances in the treatment for haematological malignancies

artículo científico publicado en 2006

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

artículo científico

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

artículo científico publicado en 2011

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

artículo científico publicado en 2004

Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease

artículo científico publicado en 2012

Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts

artículo científico publicado en 2005

Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells

artículo científico publicado en 2004

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories

artículo científico publicado en 2017

Assessment of the potential hazard represented by natural raw materials containing mineral fibres-The case of the feldspar from Orani, Sardinia (Italy).

artículo científico publicado en 2018

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

artículo científico publicado en 2012

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

artículo científico publicado en 2003

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

artículo científico publicado en 2010

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

artículo científico publicado en 2011

BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia

artículo científico publicado en 2013

Babesia infection in Italy

artículo científico publicado en 2004

Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model

artículo científico publicado en 2012

Best Practices in Chronic Myeloid Leukemia Monitoring and Management

artículo científico publicado en 2016

Blinatumomab in Ph+ B-ALL: present and perspectives

artículo científico publicado en 2017

Bone marrow of a patient with acute non-lymphoblastic leukaemia associated with the t(1;7)(p11;p11) chromosomal translocation

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

artículo científico publicado en 2013

CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.

artículo científico publicado en 2011

CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Chemotherapy during pregnancy: what is really safe?

artículo científico publicado en 2004

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia

artículo científico publicado en 2017

Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells

artículo científico publicado en 2013

Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.

artículo científico publicado en 2004

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

artículo científico publicado en 2003

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial

artículo científico publicado en 2008

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

artículo científico publicado en 2011

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

artículo científico publicado en 2018

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop

artículo científico publicado en 2011

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

artículo científico

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

artículo científico publicado en 2009

Chronic myeloid leukemia: the basis of treatment for tomorrow

artículo científico publicado en 2011

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

artículo científico publicado en 2011

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

artículo científico publicado en 2014

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

artículo científico publicado en 2003

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

artículo científico publicado en 2005

Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation

artículo científico publicado en 2008

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

artículo científico publicado en 2016

Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels

artículo científico publicado en 2009

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

artículo científico publicado en 2006

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

artículo científico publicado en 2017

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

artículo científico publicado en 2009

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient

artículo científico publicado en 2010

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

artículo científico publicado en 2003

Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities

Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors.

artículo científico publicado en 2003

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

artículo científico publicado en 2016

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study

artículo científico publicado en 2016

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

artículo científico publicado en 2017

Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia

artículo científico publicado en 2002

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

artículo científico publicado en 2003

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments

artículo científico publicado en 2012

DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia.

artículo científico publicado en 2012

DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia

artículo científico publicado en 2015

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

artículo científico

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

artículo científico publicado en 2010

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

artículo científico publicado en 2011

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

artículo científico publicado en 2007

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

artículo científico publicado en 2005

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

artículo científico publicado en 2010

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

artículo científico publicado en 2004

Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry

artículo científico publicado en 2004

Dissecting the role of aberrant DNA methylation in human leukaemia

artículo científico publicado en 2015

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

artículo científico publicado en 2004

ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication.

artículo científico publicado en 2007

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

artículo científico publicado en 2008

Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity

artículo científico publicado en 2005

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

artículo científico publicado en 2003

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

artículo científico publicado en 2006

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.

artículo científico publicado en 2016

Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report

artículo científico publicado en 2013

Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma

artículo científico publicado en 2013

Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase

artículo científico publicado en 2004

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

artículo científico publicado en 2009

Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells

artículo científico publicado en 2017

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

artículo científico publicado en 2013

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

artículo científico publicado en 2008

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).

artículo científico publicado en 2015

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

artículo científico publicado en 2016

FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features.

artículo científico publicado en 2016

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage

artículo científico publicado en 2017

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

artículo científico publicado en 2013

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

artículo científico publicado en 2008

First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy

artículo científico publicado en 2006

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

artículo científico publicado en 2004

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial

artículo científico publicado en 2011

Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial

artículo científico publicado en 2018

Fludarabine combination regimen severely affected peripheral blood stem cell mobilization

artículo científico publicado en 2004

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

artículo científico publicado en 2008

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

artículo científico publicado en 2010

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

artículo científico publicado en 2004

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years

artículo científico publicado en 2008

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells

article

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

artículo científico publicado en 2006

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.

artículo científico publicado en 2007

High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment

artículo científico publicado en 2007

IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells

artículo científico publicado en 2004

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

artículo científico publicado en 2012

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

artículo científico publicado en 2009

IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia

artículo científico publicado en 2015

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

artículo científico publicado en 2009

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

article published in 2008

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2004

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

artículo científico publicado en 2004

Imatinib mesylate for the treatment of chronic myeloid leukemia

artículo científico publicado en 2008

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

artículo científico publicado en 2005

Imatinib mesylate in the treatment of hematologic malignancies

artículo científico publicado en 2007

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

artículo científico publicado en 2007

Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

article

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

artículo científico

Imputation reliability on DNA biallelic markers for drug metabolism studies

artículo científico publicado en 2012

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

artículo científico publicado en 2016

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

artículo científico publicado en 2015

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

artículo científico publicado en 2008

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

artículo científico publicado en 2009

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini

artículo científico publicado en 2012

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

Interferon in CML: back to the past, or towards the future?

artículo científico publicado en 2015

Interferon-alfa for chronic myeloid leukemia

artículo científico publicado en 2003

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

artículo científico publicado en 2009

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

artículo científico publicado en 2008

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

artículo científico publicado en 2015

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2016

Intrathecal chemotherapy in carcinomatous meningitis from breast cancer

artículo científico publicado en 2002

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

artículo científico publicado en 2015

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

artículo científico publicado en 2009

Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients

artículo científico publicado en 2016

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

artículo científico publicado en 2005

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

artículo científico publicado en 2008

Locked-in syndrome after basilary artery thrombosis by mucormycosis masquerading as meningoencephalitis in a lymphoma patient

scientific article published on 19 December 2013

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

artículo científico publicado en 2010

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

artículo científico publicado en 2008

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

artículo científico publicado en 2007

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

artículo científico publicado en 2011

Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer

artículo científico publicado en 2004

Management of anaplastic large-cell lymphoma during pregnancy

artículo científico publicado en 2009

May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?

artículo científico publicado en 2006

Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia

artículo científico publicado en 2008

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

artículo científico publicado en 2009

Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe

artículo científico publicado en 2003

Molecular monitoring

artículo científico publicado en 2014

Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia

artículo científico publicado en 2013

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

artículo científico publicado en 2003

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

artículo científico publicado en 2003

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio

artículo científico publicado en 2007

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

artículo científico publicado en 2006

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

artículo científico publicado en 2006

Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells

artículo científico publicado en 2008

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

artículo científico publicado en 2005

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

artículo científico

N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

artículo científico publicado en 2005

NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2015

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.

artículo científico publicado en 2009

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia

scientific article published on June 2009

New targets for Ph+ leukaemia therapy

scientific article published on September 2009

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2014

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

artículo científico publicado en 2007

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia

article

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

artículo científico publicado en 2010

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

artículo científico publicado en 2007

No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?

artículo científico publicado en 2004

Novel FLT3 point mutation in acute myeloid leukaemia

artículo científico publicado en 2003

Nuclear factor kB as a target for new drug development in myeloid malignancies

artículo científico publicado en 2007

Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta

artículo científico publicado en 2013

On the possible origin of thermal infrared radiation (TIR) anomalies in earthquake-prone areas observed using robust satellite techniques (RST)

scholarly article

Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products

artículo científico publicado en 2004

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

artículo científico publicado en 2017

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation

artículo científico publicado en 2009

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

artículo científico publicado en 2017

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

artículo científico publicado en 2009

Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera

artículo científico publicado en 2007

Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.

artículo científico publicado en 2006

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

artículo científico publicado en 2016

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

artículo científico publicado en 2010

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

artículo científico publicado en 2009

Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias

artículo científico publicado en 2005

Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.

artículo científico publicado en 2008

Plerixafor and Filgrastim XM02 (Tevagastrim®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation ⬇️

artículo científico publicado el 17 de noviembre de 2011

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

artículo científico publicado en 2011

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule

artículo científico publicado en 2014

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function

artículo científico publicado en 2009

Present and future of molecular monitoring in chronic myeloid leukaemia

artículo científico publicado en 2016

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

artículo científico publicado en 2006

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

artículo científico publicado en 2016

Primary cardiac lymphoma with isolated parenchymal central nervous system relapse: report of two cases and review of the literature

artículo científico publicado en 2014

Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion.

artículo científico publicado en 2006

Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders

artículo científico publicado en 2011

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia

artículo científico publicado en 2008

Procalcitonin as a useful marker of infection in hemato-oncological patients with fever

artículo científico publicado en 2008

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

artículo científico publicado en 2004

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

artículo científico publicado en 2004

Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions

artículo científico publicado en 2004

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

artículo científico publicado en 2013

Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia

artículo científico publicado en 2010

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

artículo científico publicado en 2018

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

artículo científico publicado en 2014

RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia

artículo científico publicado en 2010

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

artículo científico publicado en 2015

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

artículo científico publicado en 2003

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2013

Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment

artículo científico publicado en 2014

Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome

artículo científico publicado en 2013

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

artículo científico publicado en 2009

Relationship between genome and epigenome--challenges and requirements for future research

artículo científico publicado en 2014

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia

artículo científico publicado en 2014

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

artículo científico publicado en 2015

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients

artículo científico publicado en 2015

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

artículo científico publicado en 2003

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study

artículo científico publicado en 2010

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

artículo científico publicado en 2010

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

artículo científico publicado en 2011

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

artículo científico publicado en 2009

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study

artículo científico publicado en 2017

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

artículo científico publicado en 2013

Sexuality in patients undergoing haematopoietic stem cell transplantation

artículo científico publicado en 2011

Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies

artículo científico publicado en 2016

Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor

artículo científico publicado en 2017

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

artículo científico publicado en 2004

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

artículo científico publicado en 2013

Stroma cells: a novel target of herceptin activity

artículo científico publicado en 2003

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

artículo científico publicado en 2009

Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature

artículo científico publicado en 2012

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells

artículo científico publicado en 2008

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat

artículo científico publicado en 2004

Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblastic leukemia

artículo científico publicado en 2017

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

scholarly article by Andrea Ghelli Luserna Di Rorà published in August 2018

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

artículo científico publicado en 2016

The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia

artículo científico publicado en 2009

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

artículo científico publicado en 2013

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

artículo científico publicado en 2015

The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party

artículo científico publicado en 2010

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

artículo científico publicado en 2004

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

artículo científico publicado en 2017

The cytogenetic response as a surrogate marker of survival

artículo científico publicado en 2003

The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations

artículo científico publicado en 2014

The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells

artículo científico publicado en 2016

The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.

artículo científico publicado en 2014

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study

artículo científico publicado en 2017

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

artículo científico publicado en 2010

The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution

artículo científico publicado en 2009

The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification.

artículo científico publicado en 2005

Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2014

Treatment for patients with indolent and mantle cell lymphoma

artículo científico publicado en 2013

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells

artículo científico publicado en 2015

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

artículo científico publicado en 2015

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

artículo científico publicado en 2007

Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

artículo científico publicado en 2014

Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia

artículo científico publicado en 2013

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2011

Who should be really considered as a poor mobilizer in the plerixafor era?

artículo científico publicado en 2012

c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration

artículo científico publicado en 2010

cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib

artículo científico

mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein

artículo científico publicado en 2009

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase

artículo científico publicado en 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda